Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast

Histopathology

Volumn 49, Issue 1, 2006, Pages 22-34

  Fulford, L G ^a,b,h   Easton, D F ^c   Reis Filho, J S ^a,d   Sofronis, A ^a,b   Gillett, C E ^e   Lakhani, S R ^f   Hanby, A ^g  

^a Breakthrough Breast Cancer Research Centre   (United Kingdom)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d UNIVERSITY OF PORTO   (Portugal)

^e GUY S HOSPITAL   (United Kingdom)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g UNIVERSITY OF LEEDS   (United Kingdom)

^h Rockefeller Building ^*  (United Kingdom)

Author keywords

Basal phenotype; Breast carcinoma; Pathology; Prognosis

Indexed keywords

CYTOKERATIN 14;

ARTICLE; BREAST CARCINOMA; CANCER INVASION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MICROMORPHOLOGY; MITOSIS RATE; MORPHOLOGICAL TRAIT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-14; KERATINS; NEOPLASMS, BASAL CELL; PHENOTYPE; TUMOR MARKERS, BIOLOGICAL;

ACARI;

EID: 33745660509     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2006.02453.x     Document Type: Article

References (41)

1. Gusterson BA, Warburton MJ, Mitchell D et al. Distribution of myoepithelial cells and basement membrane proteins in the normal breast and in benign and malignant breast diseases. Cancer Res. 1982; 42; 4763-4770.
2. Nagle RB, Bocker W, Davis JR et al. Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J. Histochem. Cytochem. 1986; 34; 869-881.
3. Gould VE, Koukoulis GK, Jansson DS et al. Coexpression patterns of vimentin and glial filament protein with cytokeratins in the normal, hyperplastic, and neoplastic breast. Am. J. Pathol. 1990; 137; 1143-1155.
4. Wetzels RH, Kuijpers HJ, Lane EB et al. Basal cell-specific and hyperproliferation-related keratins in human breast cancer. Am. J. Pathol. 1991; 138; 751-763.
5. Heatley M, Maxwell P, Whiteside C et al. Cytokeratin intermediate filament expression in benign and malignant breast disease. J. Clin. Pathol. 1995; 48; 26-32.
6. Malzahn K, Mitze M, Thoenes M, Moll R. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch. 1998; 433; 119-129.
7. Tsuda H, Takarabe T, Hasegawa T et al. Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones. Hum. Pathol. 1999; 30; 1134-1139.
8. Jones C, Nonni AV, Fulford L et al. CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br. J. Cancer 2001; 85; 422-427.
9. van de Rijn M, Perou CM, Tibshirani R, Brown P. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am. J. Pathol. 2002; 161; 1991-1996.
10. Abd El-Rehim DM, Pinder SE, Paish CE et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J. Pathol. 2004; 203; 661-671.
11. Kesse-Adu R, Shousha S. Myoepithelial markers are expressed in at least 29% of oestrogen receptor negative invasive breast carcinoma. Mod. Pathol. 2004; 17; 646-652.
12. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004; 10; 5367-5374.
13. Arnes JB, Brunet JS, Stefansson I et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin. Cancer Res. 2005; 11; 4003-4011.
14. Rouzier R., Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 2005; 11; 5678-5685.
15. Laakso M, Loman N, Borg A et al. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod. Pathol. 2005; 18; 1321-1328.
16. Matos I, Dufloth R, Alvarenga M et al. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005; 447; 688-689.
17. Tsuda H, Takarabe T, Hasegawa F et al. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am. J. Surg. Pathol. 2000; 24; 197-202.
18. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406; 747-752.
19. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 2001; 98; 10869-10874.
20. Jones C, Ford E, Gillett C et al. Molecular cytogenetic identification of sub-groups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin. Cancer Res. 2004; 10 (18 Part 1); 5988-5997.
21. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19; 403-410.
22. Page DL, Jensen RA, Simpson JF. Routinely available indicators of prognosis in breast cancer. Breast Cancer Res. Treat. 1998; 51; 195-208.
23. Page DL. Special types of invasive breast cancer, with clinical implications. Am. J. Surg. Pathol. 2003; 27; 832-835.
24. Tot T. The cytokeratin profile of medullary carcinoma of the breast. Histopathology 2000; 37; 175-181.
25. Fisher ER, Osborne CK, McGuire WL et al. Correlation of primary breast cancer histopathology and estrogen receptor content. Breast Cancer Res. Treat. 1981; 1; 37-41.
26. Lakhani SR, Jacquemier J, Sloane JP et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl Cancer Inst. 1998; 90; 1138-1145.
27. Lakhani SR, Reis-Filho JS, Fulford L et al. Breast Cancer Linkage Consortium. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin. Cancer Res. 2005; 11; 5175-5180.
28. Foulkes WD, Stefansson IM, Chappuis PO et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl Cancer Inst. 2003; 95; 1482-1485.
29. Gillett CE, Miles DW, Ryder K et al. Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J. Pathol. 2001; 193; 433-441.
30. Landis J, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33; 159-174.
31. Lynch J, Pattekar R, Barnes DM et al. Mitotic counts provide additional prognostic information in grade II mammary carcinoma. J. Pathol. 2002; 196; 275-279.
32. Kato T, Kameoka S, Kimura T et al. p53, mitosis, apoptosis and necrosis as prognostic indicators of long-term survival in breast cancer. Anticancer Res. 2002; 22; 1105-1112.
33. Armes JE, Egan AJ, Southey MC et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 1998; 83; 2335-2345.
34. Yagata H, Harigaya K, Suzuki M et al. Comedonecrosis is an unfavorable marker in node-negative invasive breast carcinoma. Pathol. Int. 2003; 53; 501-506.
35. Ridolfi RL, Rosen PP, Port A et al. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer 1977; 40; 1365-1385.
36. Pedersen L, Holck S, Schiodt T et al. Medullary carcinoma of the breast, prognostic importance of characteristic histopathological features evaluated in a multivariate Cox analysis. Eur. J. Cancer 1994; 30A; 1792-1797.
37. Wargotz ES, Deos PH, Norris HJ. Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. Hum. Pathol. 1989; 20; 732-740.
38. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. IV. Squamous cell carcinoma of ductal origin. Cancer 1990; 65; 272-276.
39. Reis-Filho JS, Milanezi F, Paredes J et al. Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. Appl. Immunohistochem. Mol. Morphol. 2003; 11; 1-8.
40. Dunne B, Lee AH, Pinder SE et al. An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast. Hum. Pathol. 2003; 34; 1009-1015.
41. Reis Filho JS, Milanezi F, Simpson P et al. Are metaplastic breast carcinomas basal-like tumours? Mod. Pathol. 2005; 18 (Suppl. 1); 48A (Abstract).